Van ECK Associates Corp lowered its position in United Therapeutics Corporation (NASDAQ:UTHR) by 11.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 76,842 shares of the biotechnology company’s stock after selling 9,672 shares during the period. Van ECK Associates Corp’s holdings in United Therapeutics Corporation were worth $11,021,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the company. Nordea Investment Management AB boosted its position in United Therapeutics Corporation by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock worth $128,000 after buying an additional 190 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in United Therapeutics Corporation by 9.5% in the third quarter. Daiwa Securities Group Inc. now owns 1,150 shares of the biotechnology company’s stock worth $136,000 after buying an additional 100 shares in the last quarter. BancorpSouth Inc acquired a new position in United Therapeutics Corporation during the third quarter worth $224,000. Zweig DiMenna Associates LLC acquired a new position in United Therapeutics Corporation during the third quarter worth $224,000. Finally, Neuberger Berman Group LLC acquired a new position in United Therapeutics Corporation during the third quarter worth $233,000.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded up 0.38% during midday trading on Tuesday, hitting $165.10. The stock had a trading volume of 124,787 shares. The stock has a 50 day moving average of $154.35 and a 200-day moving average of $132.37. The company has a market cap of $7.00 billion, a P/E ratio of 11.17 and a beta of 1.42. United Therapeutics Corporation has a one year low of $97.52 and a one year high of $166.68.
“United Therapeutics Corporation (UTHR) Position Lowered by Van ECK Associates Corp” was posted by sleekmoney and is the property of of sleekmoney. If you are reading this story on another site, it was illegally copied and republished in violation of United States and international copyright & trademark laws. The original version of this story can be read at http://sleekmoney.com/united-therapeutics-corporation-uthr-position-lowered-by-van-eck-associates-corp/1660444.html.
A number of equities analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corporation in a report on Friday, November 4th. Zacks Investment Research lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, December 28th. Standpoint Research lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, January 19th. Barclays PLC lowered United Therapeutics Corporation from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $115.00 to $100.00 in a research note on Tuesday, November 29th. Finally, Ladenburg Thalmann Financial Services raised United Therapeutics Corporation from a “neutral” rating to a “buy” rating and increased their target price for the stock from $128.00 to $138.00 in a research note on Friday, October 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $136.42.
In other news, CEO Martine A. Rothblatt sold 1,233 shares of the firm’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $132.81, for a total transaction of $163,754.73. Following the completion of the transaction, the chief executive officer now owns 1,373 shares of the company’s stock, valued at $182,348.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,246 shares of the firm’s stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $126.86, for a total transaction of $158,067.56. Following the transaction, the chief executive officer now directly owns 1,386 shares of the company’s stock, valued at approximately $175,827.96. The disclosure for this sale can be found here. In the last three months, insiders sold 21,010 shares of company stock valued at $2,892,349. 7.50% of the stock is owned by insiders.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/united-therapeutics-corporation-uthr-position-lowered-by-van-eck-associates-corp/1660444.html
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.